Benedetta Massetto

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Edward Gane, Wai Kay Seto, Henry Lik‐Yuen Chan et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 546 citations

Pharmacy, Infectious Diseases, Pharmacology +12

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Henry Lik‐Yuen Chan, Scott Fung, Wai Kay Seto et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 458 citations

Pharmacy, Infectious Diseases, Pharmacology +11

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Graham R. Foster, Stephen Pianko, Ashley Brown et al. · Gastroenterology · 2015 · 250 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B

Harry L.A. Janssen, Maurizia Rossana Brunetto, Yoon Jun Kim et al. · Journal of Hepatology · 2017 · 201 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infection

William F. Balistreri, Karen F. Murray, Philip Rosenthal et al. · Hepatology · 2016 · 197 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17